Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Clearmind Medicine Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CMND
Nasdaq
2830
www.clearmindmedicine.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Clearmind Medicine Inc.
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
- Feb 9th, 2026 6:17 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Feb 8th, 2026 1:50 pm
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
- Feb 6th, 2026 5:55 am
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
- Feb 6th, 2026 5:55 am
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
- Feb 3rd, 2026 6:00 am
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
- Jan 20th, 2026 2:20 pm
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
- Jan 14th, 2026 6:55 am
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Dec 31st, 2025 7:10 am
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
- Dec 24th, 2025 7:15 am
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
- Dec 16th, 2025 6:45 am
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
- Dec 12th, 2025 6:32 am
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
- Dec 12th, 2025 4:32 am
Clearmind Medicine Announces 1-for-40 Reverse Share Split
- Dec 10th, 2025 2:15 pm
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
- Dec 5th, 2025 3:00 pm
BC-Most Active Stocks
- Dec 2nd, 2025 8:30 am
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
- Dec 2nd, 2025 5:57 am
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial
- Dec 1st, 2025 6:56 am
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial
- Nov 25th, 2025 5:17 am
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review
- Nov 24th, 2025 6:51 am
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
- Nov 20th, 2025 4:42 am
Scroll